Tetradecylacetate

Tetradecylacetate

SCHEMBL633019

CC(O)CO.CCCCCCCCCCCCCCOC(C)=O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Tetradecylacetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.61
TSHR P16473 2/20 0.50
NAAA Q02083 1/20 0.50
MAPT P10636 1/20 0.47
EPHX1 P07099 1/20 0.47
USP2 O75604 1/20 0.46
KDM4E B2RXH2 1/20 0.45
DUSP3 P51452 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 1/20 0.45
CES2 O00748 1/20 0.44
PRKCA P17252 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Octyl Acetate SCHEMBL27849660 1.00 ALDH1A1 (0.61) ALDH1A1TSHRNAAAMAPTEPHX1
Acetic Acid Pentyl Ester SCHEMBL27685689 0.98 ALDH1A1 (0.63) ALDH1A1TSHRNAAAMAPTEPHX1
Hexyl Acetate SCHEMBL896029 0.93 ALDH1A1 (0.53) ALDH1A1TSHRNAAAMAPTEPHX1
Tetradecylacetate SCHEMBL466058 0.93 ALDH1A1 (0.53) ALDH1A1TSHRNAAAMAPTEPHX1
Acetic Acid Butyl Ester SCHEMBL2700544 0.92 ALDH1A1 (0.72) ALDH1A1TSHRMAPTKDM4EDUSP3
Acetic Acid Pentyl Ester SCHEMBL27678839 0.91 ALDH1A1 (0.60) ALDH1A1TSHRNAAAMAPTEPHX1
Acetic Acid Pentyl Ester SCHEMBL2269446 0.91 ALDH1A1 (0.55) ALDH1A1TSHRNAAAMAPTEPHX1
Hexyl Acetate SCHEMBL27795514 0.89 ALDH1A1 (0.61) ALDH1A1TSHRNAAAEPHX1USP2
Acetic Acid Butyl Ester SCHEMBL28255898 0.89 ALDH1A1 (0.67) ALDH1A1TSHRMAPTKDM4EDUSP3
Acetic Acid Pentyl Ester SCHEMBL27737254 0.88 ALDH1A1 (0.71) ALDH1A1TSHRNAAAMAPTEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3242687-B1 NANOPARTICLES AND METHODS FOR PREPARATION THEREOF B G NEGEV TECHNOLOGIES AND APPLICATIONS LTD AT BEN GURION UNIV (IL) 2020-12-30 EP claimed
US-20180104347-A1 NANOPARTICLES AND METHODS FOR PREPARATION THEREOF B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD. AT BEN-GURION UNIVERSITY (IL) 2018-04-19 US claimed
EP-3242687-A1 NANOPARTICLES AND METHODS FOR PREPARATION THEREOF B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) 2017-11-15 EP claimed
WO-2016110839-A1 NANOPARTICLES AND METHODS FOR PREPARATION THEREOF B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) 2016-07-14 WO claimed
US-20100034880-A1 PHARMACEUTICAL COMPOSITIONS BASED ON A MICROEMULSION NANODERMA LTD (IL) 2010-02-11 US claimed
EP-2120863-A1 PHARMACEUTICAL COMPOSITIONS BASED ON A MICROEMULSION Nanoderma Ltd. (IL) 2009-11-25 EP claimed
WO-2008096351-A1 PHARMACEUTICAL COMPOSITIONS BASED ON A MICROEMULSION NANODERMA LTD. (IL) 2008-08-14 WO claimed
US-7101563-B1 Micronized vitamin C formulation AUSTRALIAN IMPORTERS, LTD. (US) 2006-09-05 US claimed
EP-1558206-A1 FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE Australian Importers, Ltd (US) 2005-08-03 EP claimed
WO-2004039348-A1 FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE AUSTRALIAN IMPORTERS, LTD. (US) 2004-05-13 WO claimed
US-20040081681-A1 Anhydrous formulations for percutaneous absorption AUSTRALIAN IMPORTERS 2004-04-29 US claimed
EP-4727581-A2 PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOACTIVE AGENTS WITH IMPROVED BIOAVAILABILITY AND METHODS OF USE Shapiro, Scott (US) 2026-04-22 EP disclosed
US-12453753-B2 Oxygenated cannabis skin therapy compositions and methods for producing the compositions Pauwels, David (US) 2025-10-28 US disclosed
US-12409121-B2 Formulations and methods for preparing stable cosmetic compositions Spinart, LLC (US) 2025-09-09 US disclosed
WO-2024259323-A2 PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOACTIVE AGENTS WITH IMPROVED BIOAVAILABILITY AND METHODS OF USE SHAPIRO SCOTT (US) 2024-12-19 WO disclosed
EP-0522618-A1 Coloured cosmetic sticks UNILEVER N.V. (NL) 1993-01-13 EP disclosed
US-5176902-A Esterified wax, aluminum lake dye ELIZABETH ARDEN COMPANY, DIVISION OF CONOPCO, INC. (US) 1993-01-05 US disclosed
EP-0520550-A2 Method and article for distinguishing cosmetic sticks containing water UNILEVER N.V. (NL) 1992-12-30 EP disclosed
US-5108737-A Colored cosmetic sticks ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) 1992-04-28 US disclosed
US-5085856-A Containing water, waxes, oils to provide moisturisation, protection ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) 1992-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12453753-B2 Oxygenated cannabis skin therapy compositions and methods for producing the compositions CNR2, OXER1, CNR1 ALDH1A1 2357/4885TSHR 4018/4885NAAA 888/4885
US-12409121-B2 Formulations and methods for preparing stable cosmetic compositions CUTA, ARG1, ODC1 ALDH1A1 2381/4885TSHR 3384/4885NAAA 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.